TABLE 1.
Patients clinical characteristics
| Case | BMI | Age | Comorbidities | Presenting symptoms | Chest X‐ray | paFiO2 | IOT‐ Prono time | Treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | 29.1 | 39 | Overweight | Diarrhea, fever, dry cough, and dyspnea | Bilateral ground‐glass opacification | 67 | 24h | Lung protective and prone position ventilation vasopressors, steroids, broad‐spectrum antibiotics, antiviral and anticoagulation. |
| 2 | 28.3 | 66 | Overweight and type 2 diabetes | Arthralgias, fever and dyspnea | Cardiomegaly and patchy peripheral left mid to lower lung opacities | 80 | 24h | Lung protective and prone position ventilation, antiviral and anticoagulation |
| 3 | 24.5 | 56 | Smoking | Odynophagia and dyspnea | Diffuse interstitial involvement, predominantly peripheral | 111 | 72h | Lung protective and prone position ventilation, antiviral, systemic steroids, and anticoagulation |
| 4 | 33.1 | 50 | Obesity | Odynophagia, fever, and dyspnea | Severe interstitial thickening at lower lobes | 91 | 48h | Lung protective and prone position ventilation, lopinavir/ritonavir, systemic steroids, and anticoagulation |
| 5 | 32.4 | 63 | Overweight, gout, and dyslipidemia | Dry cough, odynophagia fever, and dyspnea | Ground‐glass opacification at lung bases | 93 | 12h | Lung protective and prone position ventilation, hydroxychloroquine, azithromycin, anticoagulation, steroids, and hemodialysis |
| 6 | 35.1 | 64 | Obesity | Arthralgias, odynophagia, fever, and dyspnea | Severe peripheral interstitial involvementpredominantlyat lower lobes | 52 | 6h | Lung protective and prone position ventilation, systemic steroids, and hemodialysis |
| 7 | 24.9 | 64 | Type 2 diabetes and hypertension | Lipothymy, AV block, and fever | Peripheralbilateral ground‐glass opacification | 76 | 72h | Lung protective and prone position ventilation, antiviral, systemic steroids, and anticoagulation |
| 8 | 31.1 | 79 | Obesity, type 2 diabetes, and hypertension | Arthralgia, odynophagia, fever, and dyspnea | Diffuse interstitial involvement, predominantly peripheral | 111 | 48h | Lung protective and prone position ventilation, antiviral, systemic steroids, and anticoagulation |
| 9 | 36.3 | 50 | Obesity, hypertension, hyperuricemia, gout, and dyslipidemia | Odynophagia fever and dyspnea severe | Diffuse ground glass opacities predominantly at lung bases | 96 | 5 days | Lung protective and prone position ventilation, systemic steroids, and hemodialysis |
| 10 | 24.4 | 71 | Hypertension, dyslipidemia, and ischemic heart disease | Dry cough, fever, and dyspnea | Cardiomegaly and bilateral ground‐glass opacification | 53 | 72h | Lung protective and prone position ventilation, antiviral and anticoagulation |
| 11 | 23.6 | 70 | Type 2 diabetes | Dry cough, fever, and dyspnea | Peripheral interstitial involvement and right basal consolidation | 85 | 12h | Lung protective and prone position ventilation, hydroxychloroquine, azithromycin, and anticoagulation |
| 12 | 30.2 | 52 | Obesity | Dry cough, fever, and dyspnea | Severe interstitial involvement predominantly in lung bases | 65 | 8h | Lung protective and prone position ventilation, antiviral, and anticoagulation |
| 13 | 22.9 | 66 | Type 2 diabetes | Asthenia, fever, and dyspnea | Severe interstitial involvement predominantly peripheral | 79 | 48h | Lung protective and prone position ventilation, systemic steroids, antiviral, and anticoagulation |
| 14 | 24.1 | 69 | Alcoholism | Dry cough, fever, and dyspnea | Diffuse interstitial involvement | 66 | 12h | Lung protective and prone position ventilation, antiviral, and anticoagulation |
| 15 | 34.4 | 57 | Obesity | Productive cough, fever, and dyspnea | Bilateral diffuse ground‐glass opacities | 100 | 4h | Lung protective and prone position ventilation, antiviral, and anticoagulation |